Transcription of DEVELOPING A CULTURE OF …
{{id}} {{{paragraph}}}
DEVELOPING A CULTURE OF pharmacovigilance Towards International Best PracticesBy Professor Meir Pugatch, Dr David Torstensson and Ma ayan LauferSECTIOND eveloping a CULTURE of Pharmacovigilance2 This report was commissioned by Novartis Pharmaceuticals Corporation. The views represented here are those of the authors Pugatch Consilium 2014 The moral right of the authors has been rights reserved. Without limiting the rights under copyright reserved above, no part of this publication may be reproduced, stored or introduced into a retrieval system, or transmitted, in any form or by any means (electronic, mechanical, photocopying, recording or otherwise), without the prior written permission of both the copyright owner and the a CULTURE of Pharmacovigilance3 LIST OF ABBREVIATIONS 4 EXECUTIVE SUMMARY 7 INTRODUCTION 111 THE IMPORTANCE OF MONITORING THE SAFETY OF MEDICINES 14 The biopharmaceutical R&D process Essentia
Developing a Culture of Pharmacovigilance 3 LIST OF ABBREVIATIONS 4 EXECUTIVE SUMMARY 7 INTRODUCTION 11 1 THE IMPORTANCE OF MONITORING THE SAFETY OF MEDICINES 14 1.1 The biopharmaceutical R&D process 14
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
{{id}} {{{paragraph}}}
PHASE 3 REPORT ON IMPLEMENTING THE OECD, PHASE 3 REPORT ON IMPLEMENTING THE OECD ANTI-BRIBERY CONVENTION, Phase 3 Report, The OECD, OECD ANTI-BRIBERY, The OECD Anti-Bribery, Phase, Report, Latest on BEPS – 26 February 2018, OECD, Monitoring, 12. Governance and Management, National Disability Inclusion Strategy 2017-2021, National Disability Inclusion Strategy 2017 2021 3